Viridian Therapeutics (NASDAQ:VRDN) Given New $42.00 Price Target at Truist Financial

Viridian Therapeutics (NASDAQ:VRDN) had its price objective raised by Truist Financial from $39.00 to $42.00 in a report issued on Thursday morning,Benzinga reports. Truist Financial currently has a buy rating on the stock.

VRDN has been the subject of a number of other reports. HC Wainwright lifted their price target on shares of Viridian Therapeutics from $22.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday. Royal Bank Of Canada raised their price objective on Viridian Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Tuesday, September 22nd. Wall Street Zen cut Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, October 4th. Needham & Company LLC boosted their target price on Viridian Therapeutics from $34.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Weiss Ratings upgraded Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 14th. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

Viridian Therapeutics Stock Down 1.8%

Shares of NASDAQ VRDN opened at $28.55 on Thursday. The company has a quick ratio of 16.95, a current ratio of 16.95 and a debt-to-equity ratio of 0.43. Viridian Therapeutics has a 52 week low of $13.18 and a 52 week high of $34.29. The firm has a 50-day moving average price of $21.88 and a 200 day moving average price of $21.83. The stock has a market capitalization of $3.23 billion, a price-to-earnings ratio of -7.43 and a beta of 1.07.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.21. Viridian Therapeutics had a negative net margin of 1,620.79% and a negative return on equity of 77.15%. The firm had revenue of $25.75 million for the quarter, compared to the consensus estimate of $4.72 million. Equities research analysts anticipate that Viridian Therapeutics will post -4.07 EPS for the current fiscal year.

Insider Transactions at Viridian Therapeutics

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 14,212 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total value of $348,194.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Knights of Columbus Asset Advisors LLC raised its position in shares of Viridian Therapeutics by 27.6% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 90,019 shares of the company’s stock worth $1,853,000 after purchasing an additional 19,466 shares during the last quarter. 71 West Capital Partners grew its holdings in Viridian Therapeutics by 4.1% during the 3rd quarter. 71 West Capital Partners now owns 22,282 shares of the company’s stock valued at $459,000 after buying an additional 882 shares during the last quarter. Fulcrum Asset Management LLP acquired a new stake in Viridian Therapeutics during the 3rd quarter valued at $97,000. Pictet Asset Management Holding SA grew its holdings in Viridian Therapeutics by 13.5% during the 3rd quarter. Pictet Asset Management Holding SA now owns 12,741 shares of the company’s stock valued at $262,000 after buying an additional 1,516 shares during the last quarter. Finally, AlphaCentric Advisors LLC purchased a new position in Viridian Therapeutics during the third quarter worth $216,000.

Key Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Multiple firms raised their price targets and maintained or initiated positive ratings. On Nov. 5, Leerink Partners lifted its target to $54 and RBC to $41, both with “outperform” ratings; Truist raised its target to $42 (“buy”), while Wells Fargo, Wedbush and HC Wainwright also increased targets. Leerink Partners rating
• Positive Sentiment: Viridian’s Q3 loss of $0.81 per share was narrower than analysts’ roughly $1.01–$1.02 estimate, and revenue of $25.75 million topped the $4.72 million consensus. The earnings beat may have helped support investor sentiment, although the per-share loss widened from $0.34 a year earlier. Q3 results
• Positive Sentiment: Viridian outlined commercial and pipeline milestones: Lumvoa’s launch is targeting broad coverage within six to nine months, and the company signaled a biologics license application for elegrobart in Q1 2027. Progress toward broader access and the regulatory filing could strengthen the growth outlook, though execution remains important. Lumvoa and elegrobart milestones
• Negative Sentiment: A separate valuation analysis argued VRDN could be overvalued even with its new product launch, which may temper enthusiasm following the rally and analyst target increases. Valuation analysis

About Viridian Therapeutics

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.